Home/Filings/4/0001801385-25-000002
4//SEC Filing

ROMANO KATHRYN 4

Accession 0001801385-25-000002

CIK 0001711279other

Filed

Feb 27, 7:00 PM ET

Accepted

Feb 28, 7:01 PM ET

Size

24.0 KB

Accession

0001801385-25-000002

Insider Transaction Report

Form 4
Period: 2025-02-26
ROMANO KATHRYN
Chief Accounting Officer
Transactions
  • Exercise/Conversion

    Performance Stock Units

    2025-02-285,0000 total
    Common Stock (5,000 underlying)
  • Award

    Stock Option (Right to Buy)

    2025-02-28+10,00010,000 total
    Exercise: $179.25Exp: 2035-02-28Common Stock (10,000 underlying)
  • Award

    Restricted Stock Units

    2025-02-28+2,2002,200 total
    Common Stock (2,200 underlying)
  • Tax Payment

    Common Stock

    2025-02-26$176.39/sh2,268$400,05313,354 total
  • Sale

    Common Stock

    2025-02-27$175.22/sh750$131,41512,604 total
  • Exercise/Conversion

    Common Stock

    2025-02-28+5,00017,604 total
  • Tax Payment

    Common Stock

    2025-02-28$179.25/sh2,315$414,96415,289 total
  • Exercise/Conversion

    Common Stock

    2025-02-28+7,50022,789 total
  • Tax Payment

    Common Stock

    2025-02-28$179.25/sh3,471$622,17719,318 total
  • Exercise/Conversion

    Performance Stock Units

    2025-02-287,5007,500 total
    Common Stock (7,500 underlying)
Footnotes (13)
  • [F1]Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 4,900 shares of restricted stock on February 26, 2025. 19,600 Restricted Stock Awards ("RSAs) were granted on February 26, 2021, to the Reporting Person. Each RSA represented a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSAs vested in four equal annual installments beginning on February 26, 2022.
  • [F10]The option vests in four equal annual installments beginning on February 28, 2026.
  • [F11]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date.
  • [F12]The number of RSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming the Reporting Person's continued service to the Company on all applicable vesting dates.
  • [F13]The RSUs vest in four equal annual installments with the first installment vesting on February 28, 2026.
  • [F2]The closing price on February 26, 2025 of the Company's common stock on the Nasdaq Global Select Market.
  • [F3]The sale of the shares of the Company's common stock reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on November 18, 2024 and will terminate on the earlier of August 20, 2025 or the date all trades are executed or expire under the Rule 10b5-1 trading plan.
  • [F4]The transaction was executed in multiple lots at the same price, $175.22.
  • [F5]10,000 performance stock units ("PSUs") were granted on February 28, 2023. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2023, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and one-half of the PSUs granted, or 5,000 PSUs, vested on February 28, 2024, and the remaining 5,000 PSUs vested on February 28, 2025.
  • [F6]Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 5,000 PSUs on February 28, 2025.
  • [F7]The closing price on February 28, 2025 of the Company's common stock on the Nasdaq Global Select Market.
  • [F8]15,000 PSUs were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vest ratably over a two-year period. All of the performance criteria were achieved and one-half of the PSUs granted, or 7,500 PSUs, vested on February 28, 2025.
  • [F9]Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 7,500 PSUs on February 28, 2025.

Issuer

Krystal Biotech, Inc.

CIK 0001711279

Entity typeother

Related Parties

1
  • filerCIK 0001801385

Filing Metadata

Form type
4
Filed
Feb 27, 7:00 PM ET
Accepted
Feb 28, 7:01 PM ET
Size
24.0 KB